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Abstract
Background: A combination of entinostat, all-trans retinoic acid, and doxorubicin (EAD) induces cell death and
differentiation and causes significant regression of xenografts of triple-negative breast cancer (TNBC).
Methods: We investigated the mechanisms underlying the antitumor effects of each component of the EAD
combination therapy by high-throughput gene expression profiling of drug-treated cells.
Results: Microarray analysis showed that entinostat and doxorubicin (ED) altered expression of genes related to
growth arrest, inflammation, and differentiation. ED downregulated MYC, E2F, and G2M cell cycle genes.
Accordingly, entinostat sensitized the cells to doxorubicin-induced growth arrest at G2. ED induced interferon
genes, which correlated with breast tumors containing a higher proportion of tumor-infiltrating lymphocytes. ED
also increased the expression of immune checkpoint agonists and cancer testis antigens. Analysis of TNBC
xenografts showed that EAD enhanced the inflammation score in nude mice. Among the genes differentially
regulated between the EAD and ED groups, an all-trans retinoic acid (ATRA)-regulated gene, DHRS3, was induced
in EAD-treated xenografts. DHRS3 was expressed at lower levels in human TNBC metastases compared to normal
breast or primary tumors. High expression of ED-induced growth arrest and inflammatory genes was associated
with better prognosis in TNBC patients.
Conclusions: Entinostat potentiated doxorubicin-mediated cell death and the combination induced inflammatory
signatures. The ED-induced immunomodulation may improve immunotherapy. Addition of ATRA to ED may potentiate
inflammation and contribute to TNBC regression.
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Background
All-trans retinoic acid (ATRA) induces breast cancer dif-
ferentiation [1, 2], cell death [3], and inflammation [4].
However, its limited treatment success in solid tumors
[5] may be attributed to the frequent epigenetic silencing
of the retinoic acid receptor beta (RAR-β) [6, 7]. We and
others have shown that RAR-β is underexpressed and
epigenetically silenced in breast cancer, and that histone
deacetylase inhibitors (HDACi) cause reexpression of
RAR-β and sensitize the cells to treatment [8, 9].
HDACi are currently employed in the clinic for the
treatment of a wide variety of solid and hematological ma-
lignancies [10], including breast cancer [11]. The proposed
anticancer activities of HDACi include: the induction of
apoptosis and cell cycle arrest [12, 13], the inhibition of
angiogenesis [14, 15], and the stimulation of cancer cell
differentiation [16]. Importantly, HDACi have been shown
to enhance the immunogenicity of cancer cells [17].
Although HDACi showed limited effect as single agents
to treat breast cancer, their use in combination with other
anticancer agents is currently being evaluated [11]. Studies
in advanced solid tumors in which HDACi were combined
either with doxorubicin [18] or retinoic acid [19] sug-
gested enhanced antitumor activity. Previously, we showed
that a combination of entinostat, ATRA, and low-dose
doxorubicin (EAD) effectively induced cell death and dif-
ferentiation and decreased tumor size in xenografts of
TNBC cell lines [20]. In this study, we provide insights
into additional mechanisms underlying the combined
drug effect on the decrease of tumor volume. Entinostat
and doxorubicin combination (ED) induced cell cycle
growth arrest, interferon response, and other inflamma-
tory signatures. Addition of ATRA to the entinostat and
doxorubicin combination (EAD) most effectively induced
inflammatory features in nude mice.
Methods
Patient samples, cell lines, constructs, and reagents
RNA and cDNA were generated from normal and breast
cancer tissue, as described previously [20]. MDA-MB-231
and HCC1937 cells were obtained from the American
Type Culture Collection and SUM-149 and SUM-159
cells were obtained from Dr. S. Ethier (Wayne State Uni-
versity, Detroit, MI, USA). ATRA and doxorubicin were
purchased from Sigma Chemicals. Entinostat was pro-
vided by Syndax Pharmaceuticals, LLC.
Transcriptome array and bioinformatics analysis
MDA-MB-231 cells were treated for 48 h with entinostat
(2.5 μM), ATRA (1 μM), and doxorubicin (0.2 μM) singly or
in combination. RNA was extracted using RNeasy Mini Kit
(Qiagen) and Illumina HumanHT12v4 gene expression array
was performed by the Microarray Core at Johns Hopkins.
Illumina microarray data were preprocessed by background
subtraction followed by quantile normalization using Geno-
meStudio. After preprocessing using GenomeStudio, data
were imported and analyzed using R (using base and
Bioconductor packages) and Ingenuity® Pathway Analysis
(IPA). Detailed methods are provided in Additional file 1.
Fluorescence-activated cell quantification
For cell cycle determinations, cells were permeabilized
with cold 70% ethanol and stained with propidium iod-
ide (Sigma). Samples were run on the BD FACSCalibur
system (Becton Dickinson).
Xenograft assay
Xenografts of MDA-MB-231 cells were established in six
to eight athymic nude mice by injecting 2 × 106 tumor
cells per flank, two flanks per mouse. The mice were
treated for 4 weeks, receiving entinostat (2.5 mg/kg) for
5 days/weeks oral, ATRA (5 mg/kg) 5 days/weeks i.p.,
and doxorubicin (2 mg/kg) once a week i.v.
Correlation of gene expression and patient outcome
Kaplan–Meier analysis was performed by utilizing an
extended version of the previously established breast
cancer transcriptomic database [21]. The Kaplan–Meier
survival plot, the hazard ratio with 95% confidence inter-
vals, and the logrank p value were calculated and plotted
in R using the package “survival” [22].
Statistical analysis
The cell line results were expressed as mean ± standard
errors of mean (SEM). Two-tailed Student’s t tests (95%
confidence interval) were performed on pairwise combi-
nations of data to determine statistical significance de-
fined as p < 0.05, p < 0.01, and p < 0.001. Results
of qRT-PCR using tumor xenograft cDNAs were ana-
lyzed using the median and two-tailed Mann–Whitney
test. Statistical analyses were performed using GraphPad
Prism version 5.0 (GraphPad Software, Inc.).
Results
Entinostat and doxorubicin combination induces gene
reprogramming
Previously, we showed that a combination of entinostat,
ATRA, and doxorubicin (EAD) resulted in increased cell
death and differentiation, and as a consequence, a de-
crease of tumor volume [20]. To explore additional
mechanisms of tumor regression caused by EAD, and to
identify drug targets other than RAR-β, we performed
high-throughput gene expression profiling analysis of
MDA-MB-231 cells treated with entinostat, ATRA, and
doxorubicin as single, double, and triple combinations.
An unsupervised cluster analysis using the top 10% most
differentially expressed genes across all eight different
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treatment conditions revealed clustering of vehicle with
ATRA and ED with EAD treatment groups (Fig. 1a). Prin-
cipal component analysis (PCA) revealed similar grouping
of samples on the first component and a minor batch ef-
fect on the second component (Additional file 2: Figure
S1A) which was corrected in further analysis.
Differential expression analysis identified gene expres-
sion changes (≥ 2-fold change and false discovery rate ≤
0.05) across all seven different combinations compared
to vehicle treatment (Fig. 1b). EAD and ED combination
treatments elicited the greatest number of differentially
expressed genes, at 2098 and 2152 respectively. Consist-
ent with the behavior of HDAC inhibitors, most of the
genes altered by entinostat treatment alone are upregu-
lated (228/237, or 96.2%).
Gene set analysis reveals independent and synergistic
biological roles for each treatment modality
A comprehensive analysis of the pathways regulated by
the treatment groups in comparison to vehicle was per-
formed using gene set variant analysis (GSVA) [23] on






Fig. 1 ED regulates inflammatory, arrest, and differentiation genes. a Heatmap depicting unsupervised hierarchical clustering of top 10% differentially
expressed genes in MDA-MB-231 cells following different treatments (2.5 μM entinostat, 1 μM ATRA, 0.2 μM doxorubicin). Color scale indicates log2
expression values. b Total number of genes regulated in MDA-MB-231 cells by indicated treatments. c Gene set variation analysis (GSVA) scores of
gene set analysis (GSEA) hallmark gene sets for samples in the study. Heatmap colors from blue to red represent low to high enrichment; red color bar
(right) shows false discovery rate (FDR)-adjusted p value from one-way analysis of variance (ANOVA) test comparing GSVA enrichment scores across
treatment groups. d Volcano plot (log2 fold-change (FC) vs – log10 FDR) of genes upregulated and downregulated in MDA-MB-231 cells following
treatment with ED in comparison to cells treated singly with E or D. Orange dots represent genes with at least 2-fold increase or decrease in gene
expression and FDR < 0.05. e Heatmap of disease and biological functions analysis using Ingenuity® Pathway Analysis software on ED genes. Size and
color of the boxes represent – log p value and z score, respectively. E entinostat (Ent), A all-trans retinoic acid (ATRA), D doxorubicin (Dox), Veh vehicle
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Database (MSigDB). ANOVA with multiple test correc-
tion was performed for each gene set across all treat-
ment groups to identify differentially regulated gene sets
(Fig. 1c).
ATRA treatment alone had a gene set profile similar
to vehicle while doxorubicin downregulated genes re-
lated to mitotic spindle and UV response. As described
previously for other HDACi [24], entinostat increased
expression of genes associated with angiogenesis, as well
as genes related to TNF-α, inflammatory response, apop-
tosis, early estrogen receptor (ER) response, and others
(Fig. 1c). Doxorubicin and entinostat single treatments
downregulated MYC and E2F targets and progression
through the G2M checkpoint, in comparison to vehicle
(Fig. 1c). However, the ED/EAD combination most ef-
fectively decreased expression of these genes related to
proliferation and cell-cycle progression. ED/EAD also
downregulated genes related to TGF-β, protein secre-
tion, and unfolded protein response. Interestingly, ED/
EAD combinations most effectively upregulated IFN-α,
IFN-γ, complement, TP53, and UV-response genes
(Fig. 1c). Although some of these latter pathways were
also upregulated to a lesser extent by doxorubicin or
entinostat, IFN-α and IFN-γ showed the strongest syner-
gistic enrichment following treatment with ED (Fig. 1c).
Combined entinostat and doxorubicin regulates growth
arrest, inflammation, and differentiation pathways
Due to the large gene expression effect of ED treatment,
we focused our analysis on identifying differences between
ED versus single treatments with entinostat or doxorubi-
cin. In this analysis, 868 genes were differentially expressed
(Additional file 2: Figure S1B, Additional file 3: Table S1,
and Additional file 4: Table S2), including upregulation of
cell cycle, interferon, and CTA genes and downregulation
of cell cycle genes (Fig. 1d), which suggests a synergistic
effect of ED combination treatment on inducing cell death
and inflammation (Fig. 1c).
To determine the activation of specific biological func-
tions potentially related to a decrease of tumor volume due
to EAD treatment, we performed pathway enrichment ana-
lysis using Ingenuity® Pathway Analysis (IPA) on the 868
synergistically differentially expressed genes following ED
treatment (Fig. 1e). Cancer-related pathways showed nega-
tive scores, while inflammatory response (Additional file 1:
Figure S1C), cellular movement (Additional file 2: Figure
S1D), and immune cell trafficking pathways had positive
scores (Fig. 1e and Additional file 5: Table S3). Other path-
ways related to cell death and survival, growth and prolifer-
ation, and development were also identified, with mixed
enrichment scores (Fig. 1e and Additional file 5: Table S3).
Consistent with IPA analysis, gene set enrichment ana-
lysis (GSEA) identified increased inflammation-related
(interferon alpha and gamma), cell death (upregulation
of TP53, apoptosis), and growth arrest and proliferation
(decreased G2M progression, E2F and myc targets)
gene sets in the ED gene signature (Additional file 6:
Table S4).
ED and EAD therapies induce cell growth arrest
Among the genes related to cell growth arrest and death
identified by array analysis, we validated the following
ED upregulated genes by qRT-PCR: BTG2, GADD45G,
CEBPA, CCNA1, and CDKN1C. Their mRNA expression
levels following ED treatment were 2–4.5-fold higher
than entinostat-treated MDA-MB-231 cells (Fig. 2a). In
contrast to the decrease of cyclin D1 by entinostat, ob-
served mainly in ER-positive cell lines [25], treatment of
TNBC cells with entinostat induced cyclin D1 and its tar-
get, CDK6, mRNA in comparison to vehicle-treated cells
(Additional file 7: Figure S2A). However, ED and EAD
treatment significantly decreased cyclin D1 and CDK6
mRNA, in comparison to entinostat (Additional file 7:
Figure S2A). Similarly, cyclin-D1 protein levels were higher
in entinostat-treated cells, and significantly decreased by
doxorubicin, present in ED and EAD (Fig. 2b and
Additional file 7: Figure S2B, left). On the other hand,
the level of the tumor suppressor cyclin-A (CCNA1)
protein was decreased by entinostat treatment, and
restored by doxorubicin in ED and EAD (Fig. 2b and
Additional file 7: Figure S2B, right panel).
Previously, we reported that ED therapy induces cell
death by an increase in apoptosis in cell culture and in
tumor xenografts [20]. EAD most effectively induced
apoptosis and necrosis and cell death [20]. Since we ob-
served an increase in cell growth arrest genes by ED and
EAD treatment (Fig. 2a, b), we further analyzed whether
cell growth arrest is involved in the ED and EAD-in-
duced cell death. As expected, high doses of doxorubicin
(200 nM) induced arrest at the G2 phase of the cell cycle
(Fig. 2c). Interestingly, ED increased arrest at the G2
phase in comparison to doxorubicin alone (6.25–50 nM)
in MDA-MB-231 cells (Fig. 2c), SUM-149 cells (Fig. 2d),
and HCC1937 cells (Additional file 8: Table S5), suggest-
ing that entinostat increases doxorubicin sensitivity and
growth arrest. Entinostat also significantly decreased the
S phase of the cell cycle in the three cell lines (Fig. 2c, d
and Additional file 8: Table S5), consistent with its effect
on decreasing cell proliferation [20].
ED and EAD induce interferon genes associated with
higher immune cell infiltration
Since we identified regulation of interferon (IFN) response
genes as one of the most significant pathways associated
with ED treatment (Fig. 1c and Additional file 6: Table
S4), we analyzed the expression of type-1 IFN genes in the
array, and validated expression by qRT-PCR. Hierarchical
clustering analysis of these gene sets revealed upregulation
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of IFN-α (Fig. 3A and Additional file 9: Table S6) and
IFN-γ (Additional file 10: Figure S3A and Additional file 11:
Table S7) genes by ED and EAD in comparison to doxo-
rubicin and the other groups in MDA-MB-231 cells.
Within the IFN genes, GBP1, CXCL10, IRF1, and STAT1
(Fig. 3A) were described previously to be part of a tumor
relapse-free signature in breast cancer patients [26]. By
qRT-PCR, we showed that CXCL10, IRF1, and STAT1
were induced in MDA-MB-231 by EAD (at low doses of
doxorubicin), in comparison to ED and single treatments
(Fig. 3Ba). Interferon-responsive genes, the tripartite motif
(TRIM) proteins TRIM48 and TRIM51 (Fig. 3Bb), and
interferon gamma (IFNG) (Additional file 10: Figure S3Ba)
were induced at higher levels in MDA-MB-231 cells by
ED and EAD treatments in comparison to single treat-
ments. We observed a significant increase of CXCL10 and
a trend to increase TRIM48 expression in mice xenografts
of MDA-MB-231 cells treated with ED and EAD (Fig. 3Bc).
The induction of proinflammatory genes such as CXCL10
and TRIM48 by epigenetic therapy was also observed in
another TNBC cell line, SUM-159 (Additional file 10: Fig-
ure S3Bb).
Lastly, we sought to identify the relationship of immune
infiltration in breast cancer with respect to the expression
of IFN-α (Fig. 3A) and IFN-γ (Additional file 10: Figure
S3A) genes induced by ED. Immune infiltration groups
were identified in The Cancer Genome Atlas (TCGA)
breast cancer dataset using a core set of immune genes
[27] into clusters of low, medium, and high infiltration
markers (Additional file 10: Figure S3C). Hierarchical
clustering was performed in the same TCGA samples
using these ED-induced IFN genes. There was a signifi-
cant enrichment of samples with high immune infiltration





Fig. 2 ED and EAD induce growth arrest. a qRT-PCR of few genes, related to cell growth arrest and death (identified by array analysis), in MDA-
MB-231 cells treated with entinostat (2.5 μM), ATRA (1 μM), and doxorubicin (0.2 μM) singly, and combinations, for 48 h. b Western blot analysis
of cyclin A and cyclin D1 on MDA-MB-231 cells, treated as described in text. Flow cytometry determination of percentage of cell cycle distribution of
(c) MDA-MB-231 and (d) SUM-149 cells treated with different groups containing doxorubicin 6.25–200 nM (doxorubicin 12.5 nM highlighted on right),
for 48 h. RPL39 and GAPDH used as controls for qRT-PCR and western blot, respectively. Student’s t test performed, mean (± SEM) of triplicate results
shown. *Compared to entinostat in qRT-PCR and doxorubicinin flow cytometry; #compared to entinostat in flow cytometry: *p < 0.05, **/##p < 0.01,
***p < 0.001. E entinostat, A all-trans retinoic acid, D doxorubicin (Dox), Veh vehicle, GAPDH glyceraldehyde 3-phosphate dehydrogenase
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genes, with stepwise decrease of immune infiltration
groups with lower ED-induced IFN gene expression
(Fig. 3Ca and Additional file 10: Figure S3D, Additional file 9:
Table S6, and Additional file 11: Table S7). There is a strong
correlation between ED-induced IFN-α (Fig. 3Cb, Cc) and
IFN-γ (Additional file 10: Figure S3E, F) gene scores and
immune infiltration scores (Spearman correlation =
0.72 and 0.85, respectively). A 10,000-fold gene-wise per-
mutation analysis to identify significant association be-
tween immune infiltration genes and IFN genes revealed
statistically significant association (p < 0.001) (Fig. 3Cb, Cc




Fig. 3 ED and EAD induce expression of interferon-alpha genes. (A) Hierarchical supervised clustering of expression of interferon (IFN)-α genes
against signatures of MDA-MB-231 cells following treatments. (B) qRT-PCR of (a) type 1 IFN genes (CXCL10, STAT1 and IRF1) and (b) interferon-
responsive genes (TRIM48 and TRIM51) in MDA-MB-231 cells and (c) CXCL10 and TRIM48 in xenografts of treated mice. t test used to compare
mean level of expression (± SEM) in qRT-PCR after RPL39 normalization. *Compared to entinostat or doxorubicin: *p < 0.05, **p < 0.01, ***p < 0.001.
Mann–Whitney test performed, median of CXCL10 and TRIM48 expression in xenografts shown. (C) (a) Hierarchical supervised clustering of
expression of IFN-α genes against The Cancer Genome Atlas (TCGA) RNA-seq breast cancer patient dataset (bars above identify different tumor
subtypes (PAM50) and inflammatory cell content (immune, low–high)); (b) one-way ANOVA showed significant difference across one or more
groups (#1 low, #2 medium, #3 high immune cells) and post-hoc pairwise Student t test with Bonferroni correction revealed statistically significant
differences across all groups (p < 0.05); (c) IFN-α score correlation with immune infiltration. E entinostat (Ent), A all-trans retinoic acid
(ATRA), D doxorubicin (Dox), Veh vehicle, Her2 human epidermal growth factor receptor 2, Lum luminal
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suggest that the increase of IFN genes by ED and EAD
treatment may increase the infiltration of immune cells
into the breast tumor site.
ED induces proinflammatory genes
In addition, we identified by array analysis that ED regu-
lated different inflammatory genes, including the CCL2,
CXCL16 (Fig. 4a), and TNFSF9 (Fig. 4c) cytokines, the
EGR2 and DLX3 transcription factors (Fig. 4a), the
PADI4 enzyme (Fig. 4a), the CCR3 receptor (Fig 4a), and
the SPANXN1 and SPANXN5 cancer testis antigens
(CTAs) (Fig. 4b), which are related to immune cells re-
cruitment and activation (Additional file 2: Figure S1C,
D). qRT-PCR validation showed that entinostat induced
the expression of these inflammatory genes in MDA-
MB-231 cells and this effect is further potentiated by ED
(Fig. 4). Since we observed the ED induction of the CTAs
SPANXN5 in MDA-MB-231 cells (Fig. 4b) and SPANXN1
in both MDA-MB-231 (Fig. 4b) and SUM-159 cells
(Additional file 12: Figure S4A), and the immune check-
point agonist TNFSF9/CD137L in MDA-MB-231 cells
(Fig. 4c) in the array and qRT-PCR, we studied the expres-
sion of other members of these gene families across our
treatment groups.
The CTAs CTCFL/BORIS, IL13RA2, and PRAME are
significantly induced by entinostat and further regulated
by the combination of entinostat and doxorubicin (ED)
(Fig. 4b). ED also induced the expression of different
checkpoint agonists, including the ligands ICOSL and
GITRL (Fig. 4c) in MDA-MB-231 cells. The immune
checkpoint CD80 is also induced by entinostat, and
further regulated by doxorubicin. The ligand PDL1 is in-
duced by entinostat and significantly decreased by doxo-
rubicin (Fig. 4c). The checkpoint agonist GITRL and the
cancer testis antigen IL13RA2 proteins were also in-
duced in MDA-MB-231 cells by ED and EAD treatment
(Fig. 4d and Additional file 12: Figure S4B). These pat-
terns suggest activation of the immune system by ED as
possible contributors to tumor cell death in an in-vivo
system.
EAD combination induces inflammatory features in
xenografts in nude mice
Although immune deficient, athymic nude mice retain
increased natural killer (NK) cell activity and tumoricidal
macrophages [28]. Therefore, we investigated whether
the increase in inflammatory genes in the tumor cells by
ED and EAD treatment would also be followed by an in-
crease in inflammation. The study pathologist’s quantifica-
tion of inflammation in the tumor xenografts following
the eight different treatments revealed that EAD treat-
ment, followed by ED, resulted in significantly higher in-
flammatory scores (Fig. 5A and Additional file 13: Table
S8). The inflammatory score consisted of primarily
neutrophils and macrophages, some edema, and lesser
numbers of lymphocytes.
These results in tumor xenografts showed that al-
though EAD and ED equally regulated many proinflam-
matory genes (Fig. 4), EAD treatment in vivo showed a
higher effect on the induction of inflammatory features
in nude mice.
EAD-specific inflammatory genes and regulation of DHRS3
As shown in Fig. 1a (and Additional file 2: Figure S1A)
there is a high degree of overlap of the ED and EAD sig-
natures and very few genes are unique to EAD’s triple
drug effect in MDA-MB-231 cells. In order to identify
genes that potentially contribute to the EAD’s effect on
cell death and differentiation [20] and inflammation, we
investigated differentially expressed genes between EAD
and ED (Fig. 5B).
EAD treatment induced ELF3 and IL-1β in comparison
to ED (Fig. 5B). Previously, we have described ELF3 as
an EAD-induced gene with a role in differentiation ([20]
and Fig. 5C). In addition, EAD upregulates DHRS3,
CCL26, TNFα, CD14, IL-1α, and others (Fig. 5B and
Additional file 14: Figure S5A). qRT-PCR validation
showed that mRNA levels for the cytokine CCL26
were induced in MDA-MB-231 following EAD treat-
ment in comparison to ED and other treatments
(Fig. 5Ca). Interestingly, the dehydrogenase/reductase
member 3 (DHRS3, also known as retSDR1) which is
involved in maintaining the cellular supply of retinol
metabolites [29] was identified in the array as one the
few genes induced by ATRA in comparison to ve-
hicle. DHRS3 levels were higher in EAD-treated
MDA-MB-231 (Fig. 5Cb) and SUM-159 (Add-
itional file 14: Figure S5B) cells in comparison to ED
and were also induced by all combinations of ATRA
treatment, including the individual treatment. Simi-
larly, ATRA and to a lesser extent entinostat in-
creased DHRS3 protein levels in MDA-MB-231 cells
(Fig. 5Cc and Additional file 14: Figure S5C). Treat-
ment of MDA-MB-231 cells with EAD, in the pres-
ence of a low dose of doxorubicin (12.5 nM), was
more effective than single agents and ED in induction
of DHRS3 expression (Fig. 5Cc and Additional file 14:
Figure S5C). Treatment of cells with a high dose of
doxorubicin (200 nM) also increased DHRS3 expres-
sion and the combination with ATRA (AD) most ef-
fectively caused increased expression of this protein
(Fig. 5Cc and Additional file 14: Figure S5C). DHRS3
mRNA was also significantly higher in EAD-treated
tumors in comparison to ED or vehicle (Fig. 5D).
DHRS3 levels also tended to increase in the
EA-treated tumors in comparison to vehicle (Fig. 5D).
We also investigated DHRS3 expression in normal
breast, primary, and metastatic TNBC to correlate




Fig. 4 (See legend on next page.)
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their levels with tumor progression. Metastatic TNBCs
showed lower levels of DHRS3 in comparison to primary
tumors and normal breast (Fig. 5E). The role of ELF3,
CCL26, and DHRS3 in the induction of inflammation by
EAD remains to be determined.
ED-regulated genes are associated with better disease
outcome in TNBC patients
We next investigated whether there is a correlation of
the epigenetic therapy-induced genes with survival in
patients with TNBC. Higher expression of ED-induced
(See figure on previous page.)
Fig. 4 ED and EAD induce expression of proinflammatory genes. qRT-PCR of (a) genes associated with immune cell activation and recruitment,
(b) cancer testis antigens (CTA), and (c) immune checkpoints. t test used to compare mean level of expression (± SEM) in qRT-PCR after RPL39
normalization. *Compared to entinostat; #compared to doxorubicin: */#p < 0.05, **/##p < 0.01, ***p < 0.001. d Western blot analysis of GITRL and
IL13RA2 in MDA-MB-231 cells treated as described in text. Loading control: β-actin. E entinostat, A all-trans retinoic acid, D doxorubicin, Veh





Fig. 5 EAD induces inflammatory features and DHRS3 expression. (A) Quantification of inflammation from tumor xenografts (n = 7–10/group) of
treated mice (score 0–3) by pathologist blinded to nature of treatment. (B) Volcano plot (log2 fold-change (FC) vs – log10 p value) of genes
upregulated and downregulated in MDA-MB-231 cells following EAD in comparison to ED treatments. (C) qRT-PCR detection of (a) CCL26 and (b)
DHRS3 in MDA-MB-231 cells treated with entinostat (2.5 μM), ATRA (1 μM), and doxorubicin (200 and 12.5 nM) singly, and combinations, for 48 h;
(c) western blot analysis of DHRS3 in MDA-MB-231 cells treated as described in text. Loading control: β-actin. qRT-PCR detection of DHRS3 mRNA
levels in (D) tumor xenografts treated as indicated and (E) normal breast organoids (ORG), primary, and metastatic samples from TNBC patients. Mann–
Whitney test performed, median of DHRS3 expression in xenograft and primary samples shown. Student’s t test performed, mean (± SEM) of CCL26
and DHRS3 expression in MDA-MB-231 cells shown. RPL39 mRNA used as control in q-RT-PCR. *p < 0.05, **p < 0.01, ***p < 0.001. E entinostat, A all-trans
retinoic acid, D doxorubicin, Veh vehicle, NS not significant, NA not available
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genes such as BTG2, CEBPA, CCNA1, and GADD45G re-
lated to growth arrest, and IFNG, TNFSF9, IL1B, and
TRIM48 related to inflammatory response, significantly
correlated with a better prognosis of patients with basal/
TNBC. Longer overall survival (Fig. 6a, n = 241 patients),
relapse-free survival (Additional file 15: Figure S6A, n = 614
patients), and metastases-free survival (Additional file 15:
Figure S6B, n = 232 patients) were observed in TNBC pa-
tients with higher expression of ED-induced genes.
Discussion
Previously, we have demonstrated that a combination of
entinostat, ATRA, and doxorubicin (EAD) resulted in
the greatest induction of cell death and cancer stem cell
differentiation, and in consequence inhibition of xeno-
grafts of TNBC cells [20]. In this article, we show add-
itional mechanisms likely to be involved in EAD-
mediated decrease of tumor volume. Global gene ex-
pression analysis of TNBC cells following EAD and sin-
gle treatments revealed that ED is a potent gene
reprogramming therapy, and differentially regulated the
expression of many genes more efficiently than single
agents (Fig. 1).
We speculate that this ED effect on gene expression
could be attributed to the inhibition of topoisomerase
II-beta by both agents, as we have described previously
in the case of RAR-β induction [20]. Pathway analysis
showed that ED treatment regulated genes related to in-
flammation, growth arrest, and differentiation (Fig. 1).
ED downregulated MYC and E2F targets and genes
related to progression through the G2M checkpoint
(Fig. 1). Recently, Topper et al. [30] showed that the
combination of HDAC and DNA methyltransferase in-
hibitors decreased MYC-driven cell proliferation in lung
cancer. In line with this finding related to the regulation
of cell cycle arrest and death genes, we observed
that entinostat treatment sensitized TNBC cells to
doxorubicin-induced G2 cell cycle arrest (Fig. 2). Retinoic
acid [3], doxorubicin [31], and HDACi [13] as single
agents were also shown to induce cell arrest. Previously,
we showed that ED and EAD increased apoptosis and
EAD is the most effective to induce necrosis [20]. Collect-
ively, these data showed that the increase in G2 cell arrest
A
B
Fig. 6 ED-induced genes correlate with better prognosis in TNBC patients. a Kaplan–Meier curves of overall survival (OS) showing correlation of
ED-induced gene expression and prognosis in basal/TNBC patients, over a period of 12 years. b Scheme summarizing conclusions of this study
on effect of EAD combination therapy in TNBCs. Ent entinostat, ATRA all-trans retinoic acid, Dox doxorubicin, HDAC histone deacetylase, RAR
retinoic acid receptor, RXR retinoid X receptor, TopoIIβ topoisomerase II beta, NCOR nuclear receptor co-repressor
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by ED and EAD (Fig. 2) led to cancer cell apoptosis and
necrosis [20] and contributed to the decrease of tumor
volume [20].
Among the inflammatory genes, ED increased the ex-
pression of interferon (IFN) genes, which correlated to
the higher levels of infiltrated immune cells in patient
breast tumors (Fig. 3). These findings suggest that the
induction of IFN genes by the epigenetic treatment may
favor immune cell recruitment to the tumor site. Type I
IFN possesses the potent ability to activate several im-
mune cell types [32, 33]. The presence of lymphocytic
infiltration in early-stage breast cancer was associated
with good prognosis and high response rates to neoadju-
vant chemotherapy [34], especially in ER−/HER2− tu-
mors [35]. Interestingly, CXCL10, IRF1, and STAT1,
shown to be expressed in breast cancers of patients who
did not relapse [26], were also induced by EAD (Fig. 3).
In addition to the regulation of interferon responsive
genes, such as members of the tripartite motif (TRIM)
family (Fig. 3), ED treatment also significantly induced
the expression of members of the cancer/testis antigens
(CTA) family in TNBC cells (Fig. 4). Epigenetic modifi-
cations including promoter hypomethylation and histone
deacetylation have important roles in CTA gene activa-
tion [36]. CTAs are protein antigens normally expressed
in a wide variety of malignant tumors but not in normal
adult tissues, except for testis, and therefore have been
viewed as attractive targets for cancer immunotherapy
[37]. Similarly, 5-azacitidine regulates interferon signal-
ing, antigen processing and presentation, cytokines/che-
mokines, and CTA genes [30, 38, 39]. In addition, we
showed that several inflammatory genes related to im-
mune cell activation and migration, including immune
checkpoints, are also epigenetically regulated and in-
duced by entinostat and further potentiated by the ED
combination (Fig. 4). In fact, HDACi have been shown
to enhance immunogenicity of cancer cells. Several
groups have reported the upregulation of natural killer
(NK) cell-activating ligands, MHC class I and II mole-
cules, components of the machinery for antigen presen-
tation, and costimulatory molecules on the surface of
cancer cells exposed to HDACi [40–42]. Entinostat po-
tentiates the effect of immune checkpoint-blocking anti-
bodies, and the combination decreased regulatory T cells
(Tregs) and myeloid derived suppressor cells (MDSC) in
mice [43], and in patients [44]. Treatment with epigen-
etic therapy prevented exhaustion of CD8+ T cells and
increased their expansion after immune-checkpoint
blockade [45]. Chemotherapy was also shown to aug-
ment tumor immunity [46]. Previously we observed that
EAD induced almost two times higher levels of necrosis
compared to ED in vitro, and in tumor xenografts [20].
The increase in the number of dying cells in tumors of
EAD-treated mice [1] may release damage-associated
molecular patterns, release antigens, and initiate an
immune response [47]. We found that entinostat in
combination with doxorubicin (ED) most effectively up-
regulated interferon response, tumor antigens, cytokines,
costimulatory molecules, and other inflammatory genes
(Figs. 1, 3, and 4), and therefore may improve immuno-
therapies. Although we observed a similar effect of ED
and EAD on the regulation of inflammatory genes,
in-vivo EAD treatment was the most effective to in-
crease the recruitment of immune cells and edema at
the tumor site of nude mice (Fig. 5), the least immune-
deficient mouse model [28].
ATRA is critical in maintaining immune homeostasis [4,
48] to differentiate myeloid-derived suppressor cells
(MDSCs) into dendritic cells (DCs) and to improve their
immunostimulatory capacity [49, 50]. Treatment of renal
cell carcinoma patients with ATRA substantially de-
creased the presence of MDSCs in peripheral blood [51].
A recent study demonstrated that in lung cancer patients,
p53 vaccine-generated immune responses were improved
if patients received a short course of ATRA [52]. Some of
the genes induced by EAD in comparison to ED, such as
ELF3 [53, 54], DHRS3, IL-1β, CCL26 [55], TNF-α, CD14,
and IL-1α (Fig. 5 and Additional file 12: Figure S4), play a
role in inflammation. DHRS3 is involved in maintaining
the cellular supply of retinol metabolites [29] and was de-
scribed to be induced by the retinoid X receptor (RXR)
rexinoid ligand bexarotene in MMTV-erbB2 mice [56].
We also observed a correlation of the epigenetic therapy-
induced genes, related to growth arrest and inflammation,
with survival in patients with TNBC. Collectively, these
data suggested that ED and EAD treatment likely potenti-
ates tumor immune surveillance.
Conclusions
Some of the mechanisms involved in the EAD-induced
decrease in tumor volume (Fig. 6b) include an increase
in differentiation and cell death [20], due to an increase
in cell cycle arrest. Entinostat potentiated doxorubicin-
mediated cell death and the combination induced in-
flammatory signatures. The ED-induced immunomodu-
lation may improve immunotherapy. Addition of ATRA
to ED may potentiate inflammation and contribute to
TNBC regression.
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Additional file 1: Additional methods. (DOCX 45 kb)
Additional file 2: Figure S1. Gene expression array profile of TNBC cells
identified entinostat and doxorubicin (ED) as a gene reprogramming
combination. (A) Principal component analysis (PCA) 3D projection of
gene expression data obtained from microarray analysis onto first three
principal components. Each ball represents a different sample; different
treatments indicated. 1 and 2 are duplicates from different batches. (B)
Venn diagram showing number of genes common (intersection) and
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unique to each indicated treatment combination. Each treatment gene
signature derived following normalization with genes present in MDA-
MB-231 cells after vehicle (DMSO) treatment. Ingenuity® Pathway Analysis
(IPA) generated network of (C) inflammatory and (D) cellular movement
signaling upregulated in MDA-MB-231 cells treated with ED combination
compared to single treatments. Color indicates genes upregulated (red)
and downregulated (green) in MDA-MB-231 cells by ED treatment. Open
and closed edges indicate genes with direct and indirect relationships
respectively. E entinostat, A all-trans retinoic acid, D doxorubicin (different
combinations). (PPTX 579 kb)
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Additional file 4: Table S2. Genes differentially expressed by ED
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Additional file 7: Figure S2. ED and EAD induce cell growth arrest. (A)
qRT-PCR of cyclin D1 (CCND1) and cyclin-dependent kinase 6 (CDK6)
(identified by array analysis) in MDA-MB-231 cells treated with entinostat
(2.5 μM), ATRA (1 μM), and doxorubicin (0.2 μM) singly, and combinations,
for 48 h. (B) ImageJ quantification of cyclin D1 (left) and cyclin A (right)
protein expression in MDA-MB-231 cells treated with entinostat (2.5 μM),
ATRA (1 μM), and doxorubicin (0.2 μM) singly, and combinations, for
48 h. *Compared to entinostat in qRT-PCR: *p < 0.05, **p < 0.01. t test
used to compare mean level of mRNA expression (± SEM), after RPL39
normalization. (PPTX 75 kb)
Additional file 8: Table S5. ED and EAD induce growth arrest in
HCC1937 TNBC cells. (DOCX 15 kb)
Additional file 9: Table S6. IFN-α genes induced by ED in MDA-MB-231
cells and correlated with immune infiltration. (DOCX 14 kb)
Additional file 10: Figure S3. ED induces interferon gamma genes
associated with an increase in tumor lymphocytes. (A) Hierarchical
supervised clustering of expression of interferon-gamma (IFN-G) genes
against signatures of MDA-MB-231 cells following treatments. (B) qRT-PCR
of (a) IFN-G in MDA-MB-231 and (b) CXCL10 and TRIM48 in SUM-159 cells
treated with EAD singly and in combinations (doxorubicin 12.5 and 200 nM).
(C) Unsupervised hierarchical cluster analysis of tumor-infiltrating lymphocyte
genes [57], used in Fig. 3C to classify immune infiltration (low, medium, and
high) in TCGA RNA-seq breast cancer patient dataset [58]. (D) Hierarchical
supervised clustering of expression of IFN-γ genes against TCGA RNA-seq
breast cancer patient dataset. Bars above identify different tumor subtypes
(PAM50) and inflammatory cell content (immune, low–high) identified in (C).
(E) One-way ANOVA showed significant difference across one or more
groups (#1 low, #2 medium, #3 high immune cells) and post-hoc pairwise
Student t test revealed statistically significant differences across all groups (p
< 0.05). (F) IFN-γ score correlation with immune infiltration. *p < 0.05, **p <
0.01, ***p < 0.001. (PPTX 538 kb)
Additional file 11: Table S7. IFN-γ genes induced by ED in MDA-MB-
231 cells and correlated with immune infiltration. (DOCX 15 kb)
Additional file 12: Figure S4. ED regulates expression of inflammatory
genes. (A) qRT-PCR of SPANXN1 in SUM-159 cells treated as described in
text (doxorubicin 200 nM). t test used to compare mean level of mRNA
expression (± SEM) after RPL39 normalization. **p < 0.01, ***p < 0.001. (B)
ImageJ quantification of GITRL, IL13RA2, and housekeeping β-actin
protein in MDA-MB-231 cells treated as described (doxorubicin 12.5 and
200 nM). (PPTX 74 kb)
Additional file 13: Table S8. Inflammation score significance in mouse
xenografts. (DOCX 14 kb)
Additional file 14: Figure S5. genesEAD regulates inflammatory genes.
qRT-PCR of TNF-α (a) and CD14 and IL1a (b) in MDA-MB-231 cells (A) and
DHRS3 in SUM-159 cells (B) treated as described in text (doxorubicin 12.5
and 200 nM). t test used to compare mean level of mRNA expression (±
SEM) after RPL39 normalization. *p < 0.05, **p < 0.01. (C) ImageJ quantifi-
cation of DHRS3 and housekeeping β-actin proteins in MDA-MB-231 cells
treated as described. (PPTX 105 kb)
Additional file 15: Figure S6. ED-induced genes correlate with a better
prognosis in TNBC patients. Kaplan–Meier curves of relapsefree survival
(RFS) (A) and metastases-free survival (DMFS) (B) showing correlation of
ED-induced gene expression and prognosis in basal/TNBC patients, over
a period of 12 years. (PPTX 378 kb)
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